Tirzepatide is the first “twincretin”, a synthetic peptide composed of 39 amino acids based on the GIP native sequence, combining the dual agonism of GIP and GLP-1 receptors and is under approval in several countries for the treatment of T2D and obesity with once-weekly subcutaneous administration [141]. This evidence concerns the gene GIP and type 2 diabetes mellitus.